5432752025-07-012025-09-305432752025-09-305432752025-03-315432752025-04-012025-09-305432752025-07-012025-09-30in-capmkt:OtherExpenses1Member5432752025-04-012025-09-30in-capmkt:OtherExpenses1Member5432752025-07-012025-09-30ItemsThatWillNotBeReclassifiedToProfitAndLoss15432752025-07-012025-09-30ItemsThatWillNotBeReclassifiedToProfitAndLoss25432752025-04-012025-09-30ItemsThatWillNotBeReclassifiedToProfitAndLoss15432752025-04-012025-09-30ItemsThatWillNotBeReclassifiedToProfitAndLoss25432752025-07-012025-09-30ItemsThatWillBeReclassifiedToProfitAndLoss15432752025-07-012025-09-30ItemsThatWillBeReclassifiedToProfitAndLoss25432752025-04-012025-09-30ItemsThatWillBeReclassifiedToProfitAndLoss15432752025-04-012025-09-30ItemsThatWillBeReclassifiedToProfitAndLoss25432752025-07-012025-09-30RelatedPartyTransactionDomain15432752025-06-30RelatedPartyTransactionDomain15432752025-09-30RelatedPartyTransactionDomain15432752025-07-012025-09-30RelatedPartyTransactionDomain25432752025-06-30RelatedPartyTransactionDomain25432752025-09-30RelatedPartyTransactionDomain25432752025-07-012025-09-30RelatedPartyTransactionDomain35432752025-06-30RelatedPartyTransactionDomain35432752025-09-30RelatedPartyTransactionDomain35432752025-07-012025-09-30RelatedPartyTransactionDomain45432752025-06-30RelatedPartyTransactionDomain45432752025-09-30RelatedPartyTransactionDomain45432752025-07-012025-09-30RelatedPartyTransactionDomain55432752025-06-30RelatedPartyTransactionDomain55432752025-09-30RelatedPartyTransactionDomain55432752025-07-012025-09-30RelatedPartyTransactionDomain65432752025-06-30RelatedPartyTransactionDomain65432752025-09-30RelatedPartyTransactionDomain65432752025-07-012025-09-30RelatedPartyTransactionDomain75432752025-06-30RelatedPartyTransactionDomain75432752025-09-30RelatedPartyTransactionDomain75432752025-07-012025-09-30RelatedPartyTransactionDomain85432752025-06-30RelatedPartyTransactionDomain85432752025-09-30RelatedPartyTransactionDomain85432752025-07-012025-09-30RelatedPartyTransactionDomain95432752025-06-30RelatedPartyTransactionDomain95432752025-09-30RelatedPartyTransactionDomain95432752025-07-012025-09-30RelatedPartyTransactionDomain105432752025-06-30RelatedPartyTransactionDomain105432752025-09-30RelatedPartyTransactionDomain105432752025-07-012025-09-30RelatedPartyTransactionDomain115432752025-06-30RelatedPartyTransactionDomain115432752025-09-30RelatedPartyTransactionDomain115432752025-07-012025-09-30RelatedPartyTransactionDomain125432752025-06-30RelatedPartyTransactionDomain125432752025-09-30RelatedPartyTransactionDomain125432752025-07-012025-09-30RelatedPartyTransactionDomain135432752025-06-30RelatedPartyTransactionDomain135432752025-09-30RelatedPartyTransactionDomain135432752025-07-012025-09-30RelatedPartyTransactionDomain145432752025-06-30RelatedPartyTransactionDomain145432752025-09-30RelatedPartyTransactionDomain145432752025-07-012025-09-30RelatedPartyTransactionDomain155432752025-06-30RelatedPartyTransactionDomain155432752025-09-30RelatedPartyTransactionDomain155432752025-07-012025-09-30RelatedPartyTransactionDomain165432752025-06-30RelatedPartyTransactionDomain165432752025-09-30RelatedPartyTransactionDomain165432752025-07-012025-09-30RelatedPartyTransactionDomain175432752025-06-30RelatedPartyTransactionDomain175432752025-09-30RelatedPartyTransactionDomain175432752025-07-012025-09-30RelatedPartyTransactionDomain185432752025-06-30RelatedPartyTransactionDomain185432752025-09-30RelatedPartyTransactionDomain185432752025-07-012025-09-30AuditorDomain15432752025-09-30Statement15432752025-07-012025-09-30Statement15432752025-09-30StatementDynamic1I1Statement15432752025-09-30StatementDynamic1I2Statement1iso4217:INRxbrli:pureiso4217:INRxbrli:shares543275ANURASNOTLISTEDINE930P01018ANUPAM RASAYAN INDIA LIMITEDMain BoardEquity2025-04-012026-03-312025-10-172025-10-14INRMillionsQuarterlySecond quarterSingle segmentManufacturing of Industrial Chemicals2025-10-1709:02:002025-10-1709:38:00trueCash Flow IndirectDeclaration of unmodified opiniontruetrueNANAfalsetrue2025-03-10https://www.anupamrasayan.com/investors/policies-practices/policy-on-related-party-transactions-and-material-subsidiariestrue1falseNot Applicable2025-07-012025-09-30UnauditedStandalone5879260000770000005956260000323384000007254400001063300003475200002764300007207700005410330000545930000054593000095530000364100001319400000413990000000041399000051800004191700001138480000103.673.67003.673.671. The above Standalone financial results for the quarter and six months ended September 30 2025 have been prepared by the Company in accordance with Regulation 33 of SEBI Listing Obligations and Disclosure Requirements Regulations 2015 as amended and were reviewed by the Audit Committee of the Board and thereafter were approved and taken on record by the Board of Directors in their meeting held on October 17 2025. <BR> 2. Based on the management approach as defined in Ind AS 108 Operating Segments the Chief Operating Decision Maker CODM evaluates the companys performance and allocates resources based on an analysis of various performance indicators of the business segments in which the company operates. The Company is primarily engaged in the business of custom synthesis and manufacturing of specialty chemicals which the management and CODM recognise as the sole business segment. Hence disclosure of segment wise information is not required and accordingly not provided. <BR> 3. The Board of Directors of the Company at its meeting held on July 15, 2025 has approved the allotment of 3914886 fully paid up equity shares at an issue price of INR 945.11 share comprising face value of INR 10 per share and premium of INR 935.11 per share on preferential allotment basis upon conversion of equal number of warrants after receipt of 75 percent amount of the issue prize of Rs 2775 million. Out of total amount of INR 2775 million received amount of INR 2768.98 have been utilised for the repayment of Loans and General Corporate purposes upto September 30 2025 as per the objects in the offer document. <BR> 4. The figures of the previous period have been re grouped rearranged and or recasted wherever considered necessary.2025-04-012025-09-30UnauditedStandalone9036200000125260000916146000058070300000-4362600002294900006847300005408000001400530000822632000093514000009351400001636500006056000022421000007109300000000710930000-32600007076700001138480000106.376.37006.376.37Other Expenses720770000Other Expenses1400530000203677700003395200000229150000159469000014130000015922700003328260000219212000026456820000136517000000926159000050399000079570000159000007890000986894000023269600002584760000052304420000113848000030310210000314486900003144869000019652000011929200001389440000011292400002518680000111101900001578000065953600006611140000327710000180490400009220000014618000049630000183370500002085573000052304420000684730000-105640000-2637660000000076500000113659000000054080000000000-65340000231600000180000000011000000-46075000047439000000097480000-11470000365440000000000004800000157366000000000000000000000231600000026860000-1518840000003917000000000385000001436090000840200008538000063808000003005180000839280000-3141200000-314120000818120000504000000Gain/(loss) on remeasurements of the defined benefits plan12620000Income tax (expense)/income on remeasurements of the defined benefits plan-44100008210000Gain/(loss) on remeasurements of the defined benefits plan-5010000Income tax (expense)/income on remeasurements of the defined benefits plan1750000-326000000Effective portion of gain/(loss) on hedging instruments in a cash flow hedge-4660000Income tax (expense)/income on effective portion of gain/(loss) on hedging instruments in a cash flow hedge1630000-3030000Effective portion of gain/(loss) on hedging instruments in a cash flow hedge0Income tax (expense)/income on effective portion of gain/(loss) on hedging instruments in a cash flow hedge00005180000-3260000Anupam Rasayan India Limited******Kiran Pallavi Investments LLC******PromoterAny other transactionLoans and advances taken that are repaidPursuant to the provisions of SEBI (LODR) Regulations, 2015, no approval of audit committee is required for the transaction. For more details, please refer note599100005991000001) The opening balance of INR. 59.91 Million includes forex restatement of INR 8.72 Million and the closing balance inlcues forex restatement is Nil 2) The transaction is for repayment of loan availed from Kiran Pallavi Investments LLC. The loan was availed in 2019 where the Company was not a listed entity and hence, the provisions of the SEBI (LODR) Regulations, 2015 were not applicable and also, at the time of availing the loan, Kiran Pallavi Investments LLC was not a related party. However, the transaction was duly approved by the Board of Directors.Anupam Rasayan India Limited******Kiran Pallavi Investments LLC******PromoterInterest paidPursuant to the provisions of SEBI (LODR) Regulations, 2015, no approval of audit committee is required for the transaction. For more details, please refer note15000000The transaction is for repayment of interest on loan availed from Kiran Pallavi Investments LLC. The loan was availed in 2019 where the Company was not a listed entity and hence, the provisions of the SEBI (LODR) Regulations, 2015 were not applicable and also, at the time of availing the loan, Kiran Pallavi Investments LLC was not a related party.Anupam Rasayan India Limited******Tangent Science Private Limited******Associate of Subsidary CompanySale of goods or services300100000Omnibus Approval granted by the Audit Committee1293900003916000087820000Anupam Rasayan India Limited******Tangent Science Private Limited******Associate of Subsidary CompanyPurchase of goods or services449000000Omnibus Approval granted by the Audit Committee185650000-135810000-98770000Anupam Rasayan India Limited******Tangent Science Private Limited******Associate of Subsidary CompanyAdvance750000000Audit Committee has approved the matter0747280000747280000Advance072 MonthsUnsecuredSupply of MaterialApproval of the audit commitee for non-interest bearing security deposit amounting to 750 million towards the performance of contract for purchase of raw material from Tangent Science Private LimitedAnupam Rasayan India Limited******Tangent Science Private Limited******Associate of Subsidary CompanyAny other transactionSale of Land83720000Audit Committee has approved the matter08372000083720000Anupam Rasayan India Limited******Tanfac Industries Limited******Subsidiary company over which a holding company exercises effective controlPurchase of goods or services477600000Omnibus Approval granted by the Audit Committee91620000187260000213550000Anupam Rasayan India Limited******Tanfac Industries Limited******Subsidiary company over which a holding company exercises effective controlDividend receivedNo approval of audit committee is required for the receipt of dividend from the subsidiary company.2316000000The value of transaction pertains to final dividend approved by the shareholders of Tanfac Industries Ltd. in Annual General Meeting, which will be received in October 2025.Anupam Rasayan India Limited******ARIL Transmodal Logistic Private Limited******Wholly-owned SubsidaryAny other transactionService availed84000000Audit Committee has approved the matter23570000-8980000-7820000Anupam Rasayan India Limited******ARIL Fluorospeciality Private Limited******Wholly-owned SubsidaryLoan400000000Audit Committee has approved the matter1860000382970000384830000Loan0.0910 YearsUnsecuredPrincipal Buisness ActivitesAnupam Rasayan India Limited******ARIL Fluorospeciality Private Limited******Wholly-owned SubsidaryInterest receivedAudit Committee has approved the matter173400004263000058240000Loan0.0910 YearsUnsecuredPrincipal Buisness ActivitesAnupam Rasayan India Limited******Jainam Intermediates Private Limited******Wholly-owned SubsidaryPurchase of goods or services340000000Omnibus Approval granted by the Audit Committee5882000010290000-38680000Anupam Rasayan India Limited******Anupam Japan GK******Wholly-owned SubsidaryAny other transactionAdvance5000000Audit Committee has approved the matter270000520000780000Anupam Rasayan India Limited******Anupam Europe AG******Wholly-owned SubsidarySale of goods or services350000000Omnibus Approval granted by the Audit Committee58530000058530000Anupam Rasayan India Limited******Anupam General Trading FZE******Wholly-owned SubsidarySale of goods or services850000000Omnibus Approval granted by the Audit Committee1877800000187780000Anupam Rasayan India Limited******Anupam USA LLC******Wholly-owned SubsidarySale of goods or services4000000000Omnibus Approval granted by the Audit Committee345146000003451460000Anupam Rasayan India Limited******Anand Desai******Managing DirectorRemunerationRemuneration of Managing Director is duly recommended by the Nomination and Remuneration Committee and approved by the Board of Directors and Shareholders of the Company2500000002500000Anupam Rasayan India Limited******Mona Desai******Whole-time DirectorRemunerationRemuneration of Whole-time Director is duly recommended by the Nomination and Remuneration Committee and approved by the Board of Directors and Shareholders of the Company25000000025000004339510000UnauditedtrueNatvarlal Vepari & Co.true2027-05-31Preferential Issues2023-12-0655000000002025-09-30trueCRISIL Ratings LimitedfalseNANANAAshish GuptaCompany Secretary and Compliance OfficerSurat2025-10-17Part or full repayment of LoansNA4296900000042969000000Notes: <br></br> 1. As the date of allotment of both the securities i.e., equity shares and warrants are different, we have mentioned the date of Extraordinary General Meeting i.e., December 06, 2023 as the Date of raising funds in the above table, which happens to be the date of approval of members for raising the funds by way of issue of equity shares and warrants under Preferential Issue. <br></br> <br></br> 2. Total issue size of Preferential Issue is mentioned in the column "Amount Raised", out of which: <br></br> <br></br> (i) Rs. 180 Crores had been received as the allotment money against 19,04,540 equity shares issued at Rs. 945.11 per share, allotted on December 19, 2023. <br></br> <br></br> (ii) Rs. 92.50 Crores had been received towards 25% upfront amount against 39,14,886 warrants allotted on January 23, 2024. <br></br> <br></br> (iii) Rs. 277.50 Crores have been received towards remaining 75% amount against the aforesaid warrants which were converted into equal number of equity shares on July 15, 2025.General Corporate PurposesNA1203100000011971000000Notes: <br></br> 1. As the date of allotment of both the securities i.e., equity shares and warrants are different, we have mentioned the date of Extraordinary General Meeting i.e., December 06, 2023 as the Date of raising funds in the above table, which happens to be the date of approval of members for raising the funds by way of issue of equity shares and warrants under Preferential Issue. <br></br> <br></br> 2. Total issue size of Preferential Issue is mentioned in the column "Amount Raised", out of which: <br></br> <br></br> (i) Rs. 180 Crores had been received as the allotment money against 19,04,540 equity shares issued at Rs. 945.11 per share, allotted on December 19, 2023. <br></br> <br></br> (ii) Rs. 92.50 Crores had been received towards 25% upfront amount against 39,14,886 warrants allotted on January 23, 2024. <br></br> <br></br> (iii) Rs. 277.50 Crores have been received towards remaining 75% amount against the aforesaid warrants which were converted into equal number of equity shares on July 15, 2025.